Quantcast

Industry news that matters to you.  Learn more

Luminex Corporation Announces Group B Streptococcus (GBS), as a Launch Menu Assay for its New Sample-to-Answer System, ARIES

Luminex Corporation (NASDAQ: LMNX) recently announced that Group B Streptococcus (group B strep, GBS) is the fifth assay planned for the launch menu of its new sample-to-answer system, ARIES™. The assay will complement Luminex’s growing portfolio of ASR and IVD products. Previously announced items in the five assay launch menu targeted for the ARIES system include: Flu A/B and RSV, HSV 1&2, Norovirus, and Clostridium difficile (C. diff).

Luminex Corporation Announces Norovirus as a Launch Menu Assay for its New Sample-to-Answer System, ARIES

Luminex Corporation (NASDAQ: LMNX) recently announced that norovirus will be the fourth assay in the launch menu for its new sample-to-answer system, ARIES™. The assay is designed to test for both GI and GII genogroups in a single, easy-to-use cassette. The previously announced items in the five assay launch menu targeted for the ARIES system also include: Flu A&B/RSV, HSV 1&2, and Clostridium difficile (C. diff). Future menu items will be announced at a later date.